Literature DB >> 23599675

Bapineuzumab, an investigational agent for Alzheimer's disease.

Farah Khorassani, Olga Hilas.   

Abstract

Entities:  

Year:  2013        PMID： 23599675      PMCID： PMC3628177     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  14 in total

1.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

Review 2.  Memantine for dementia.

Authors:  R McShane; A Areosa Sastre; N Minakaran
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

4.  2011 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2011-03       Impact factor: 21.566

5.  Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

Authors:  Michael Lee; Frederique Bard; Kelly Johnson-Wood; Celeste Lee; Kang Hu; Sue G Griffith; Ronald S Black; Dale Schenk; Peter Seubert
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

6.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

Review 7.  Current pharmacotherapy for Alzheimer's disease.

Authors:  A Lleó; S M Greenberg; J H Growdon
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

8.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

Review 9.  Apolipoprotein E and Alzheimer's disease.

Authors:  W J Strittmatter; A D Roses
Journal:  Annu Rev Neurosci       Date:  1996       Impact factor: 12.449

Review 10.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
View more
  5 in total

1.  Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

Authors:  Dolly A Parasrampuria; Leslie Z Benet; Amarnath Sharma
Journal:  AAPS J       Date:  2018-03-13       Impact factor: 4.009

Review 2.  Disease-modifying drugs in Alzheimer's disease.

Authors:  Laura Ghezzi; Elio Scarpini; Daniela Galimberti
Journal:  Drug Des Devel Ther       Date:  2013-12-06       Impact factor: 4.162

3.  An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice.

Authors:  Yu-Sung Cheng; Zih-Ten Chen; Tai-Yan Liao; Chen Lin; Howard C-H Shen; Ya-Han Wang; Chi-Wei Chang; Ren-Shyan Liu; Rita P-Y Chen; Pang-Hsien Tu
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

Review 4.  Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings.

Authors:  Pallavi Duggal; Sidharth Mehan
Journal:  J Alzheimers Dis Rep       Date:  2019-07-02

5.  Alzheimer's disease: is a vaccine possible?

Authors:  R P S Alves; M J Yang; M T Batista; L C S Ferreira
Journal:  Braz J Med Biol Res       Date:  2014-06-03       Impact factor: 2.590
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.